Adenovirus vectors as HIV-1 vaccines: where are we? What next?

AIDS. 2015 Feb 20;29(4):395-400. doi: 10.1097/QAD.0000000000000548.

Authors

Marie Patricia DʼSouza¹, Otto O Yang

Affiliation

¹ aDivision of AIDS, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland bDivision of Infectious Diseases/Department of Medicine and Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California cAIDS Healthcare Foundation, Los Angeles, California, USA.

PMID: 25630039
DOI: 10.1097/QAD.0000000000000548

No abstract available

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

AIDS Vaccines / genetics
AIDS Vaccines / immunology*
Adenoviridae*
CD8-Positive T-Lymphocytes / immunology*
Clinical Trials as Topic
Genetic Vectors / immunology*
HIV Antibodies / blood
HIV Envelope Protein gp120 / immunology
HIV Infections / genetics
HIV Infections / prevention & control*
HIV-1 / genetics
HIV-1 / immunology*
Humans

Substances

AIDS Vaccines
HIV Antibodies
HIV Envelope Protein gp120
gp120 protein, Human immunodeficiency virus 1